Pacira projects 77-79% gross margins for 2026, driven by success of its flagship product EXPAREL, which benefits from increased reimbursement, wider commercial use, and intellectual property protection extending into the 2040s. The company is expanding market reach through strategic partnerships and enhanced intellectual property protection.
Cyborg Score Rationale
Products benefitted over 2.5 million patients in 2025, generating $726 million in revenue with highest gross margins in company history. However, net margin is relatively low at 2.99%, indicating room for improvement in profitability, and recent Q4 results missed estimates.
Top Insights
EXPAREL, flagship product, generated $575.1 million in net product sales in 2025, up 5% year-over-year
Company executing five-by-30 growth strategy with disciplined capital deployment
LG Chem partnership licenses EXPAREL for South Korea and Thailand with plans to submit applications within six months
PCRX-201 (enekinragene inzadenovec) gene therapy in development for osteoarthritis treatment
Named Competitors
Noven Pharmaceuticals — Transdermal pain management and specialty pharma
Grifols — Healthcare solutions and biopharmaceuticals
Alternative technologies — Neuromodulation and device-based pain management
Recent Developments
(February 2026) Q4 2025 earnings reported $196.9M quarterly revenue (up 5% YoY) with 2026 guidance of $745-$770M total revenue